Terada, Mitsuo
Ito, Aki
Kikawa, Yuichiro
Koizumi, Kei
Naito, Yoichi
Shimoi, Tatsunori
Ishihara, Mikiya
Yamanaka, Takashi
Ozaki, Yukinori
Hara, Fumikata
Nakamura, Rikiya
Hattori, Masaya
Miyashita, Minoru
Kondo, Naoto
Yoshinami, Tetsuhiro
Takada, Masahiro
Matsumoto, Koji
Narui, Kazukata
Sasada, Shinsuke
Iwamoto, Takayuki
Hosoda, Mitsuchika
Takano, Yuko
Oba, Takaaki
Sakai, Hitomi
Murakami, Akari
Higuchi, Toru
Tsuchida, Junko
Tanabe, Yuko
Shigechi, Tomoko
Tokuda, Emi
Harao, Michiko
Kashiwagi, Shinichiro
Mase, Junichi
Watanabe, Junichiro
Nagai, Shigenori E. http://orcid.org/0000-0003-2887-6066
Yamauchi, Chikako
Yamamoto, Yutaka
Iwata, Hiroji
Saji, Shigehira
Toyama, Tatsuya
Article History
Received: 10 August 2023
Accepted: 13 September 2023
First Online: 7 October 2023
Declarations
:
: M. Terada and A. Ito have no conflict of interest. YK received honoraria from AstraZeneca, Novartis, Pfizer, Eisai, Chugai, and Daiichi Sankyo, and participated on a Data Safety Monitoring Board or Advisory Board of Daiichi Sankyo. KK received honoraria from Pfizer and Chugai. YN received research funding from ABBVIE, Ono, Daiichi Sankyo, Taiho, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai, and Bayer, and payment or honoraria from AstraZeneca, Eisai, Ono, Gardant, Takeda, Eli Lilly, Novartis, Pfizer, Chugai, PDR pharma, Nihon Kayaku, Taiho, Bristol, Bayer, Daiichi Sankyo, and MSD. MI received honoraria from Chugai, Eisai, MSD, Ono, Daiichi-Sankyo, Otsuka, and Eli Lilly. TY received honoraria from AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa-Kirin, Novartis, Pfizer and Taiho. YO received honoraria from Daiichi Sankyo, Pfizer, Kyowa Kirin, and Chugai Pharma. FH received honoraria from Pfizer, Kyowa Kirin, Eli Lilly, Chugai, Daiichi Sankyo, and Taiho. RN received honoraria from Chugai, AstraZeneca, Eli Lilly, Novartis, and Daiichi Sankyo. MH received honoraria from Eli Lilly, and Daiichi Sankyo. TY received honoraria from Pfizer, Chugai, MSD, Eli Lilly, AstraZeneca and Eisai. MT received research funding from Daiichi Sankyo, AstraZeneca, KBCRN, JBCRG, ABCSG, Yakult, Medbis and IQVIA Services Japan and received honoraria from Daiichi Sankyo, AstraZeneca, Chugai, Eli Lilly, Pfizer, Taiho, Eisai, and MSD. MK received Research funding from Daiichi Sankyo, MSD, Eli Lilly, and Gilead Sciences, received honoraria from MSD, Kyowa Kirin, and Chugai. KN received honoraria from Pfizer, Lilly, Daiichi-Sankyo, Eisai, and Chugai. TI received research funding from Pfizer, and received honoraria from Kyowa Kirin, Chugai, Exact Sciences, Takeda, Daiichi Sankyo, and AstraZeneca. MH received honoraria from Eli Lilly. HS received research funding from Eisai, and received honoraria from Daiichi Sankyo and Eli Lilly. AM received honoraria from Daiichi Sankyo, Chugai, Eli Lilly, and Pfizer, and participated on a Data Safety Monitoring Board or Advisory Board of Daiichi Sankyo. YT received research funding from Daiichi Sankyo, Eli Lilly, MSD, Taiho, and Ono. SK received honoraria from Eisai, Chugai, and Eli Lilly. JW received honoraria from Chugai, Eisai, Pfizer, Daiichi Sankyo, and Eli Lilly. SN received honoraria from Eli Lilly, Pfizer, Chugai, Taiho, Eisai, MSD, Daiichi Sankyo, and AstraZeneca. YY received research funding from Chugai, Kyowa-Kirin, Eisai, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Takeda, Eli Lilly, Pfizer, and Novartis, received honoraria from AstraZeneca, Chugai, Kyowa-Kirin, Novartis, Eli Lilly, Pfizer, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Eisai, Takeda, MSD, Sysmex, and Exact Science, participated on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Chugai, Novartis, MSD, Eli Lilly, Pfizer, and Daiichi-Sankyo, and is a member of the Board of Director of Japanese Breast Cancer Society and Japan Breast Cancer Research Group. HI received grants from Chugai, Daiichi Sankyo, and AstraZeneca, consulting fees from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, and Giliead, and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. SS received research funding from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, and Daiichi Sankyo, received honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nippon Kayaku, participated on a Data Safety Monitoring Board or Advisory Board of Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD, is an executive member of JBCRG, JBCS, JSMO, and BIG. TT received research funding from Chugai and Eisai, and received honoraria from Eli Lilly, MSD, Pfizer, Daiichi-Sankyo, and Chugai.